Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Granel

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Acta Dermato-Venereologica|March 19, 2015
Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinomaThomas Jouary, Emeline Kubica, Stéphane Dalle, et al.
Cancer|December 8, 2024
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational studyIona Campo Le Brun, Séphane Dalle, Laurent Mortier, et al.
Journal of Hypertension|September 1, 2007
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS studyJoël Constans, Christine Germain, Philippe Gosse, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM networkRobin Zagala, Stephane Dalle, Marie Beylot-Barry, et al.
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2013
(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trialFlorent Cachin, Elisabeth Miot-Noirault, Brigitte Gillet, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Acta Dermato-Venereologica|March 19, 2015
Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinomaThomas Jouary, Emeline Kubica, Stéphane Dalle, et al.
Cancer|December 8, 2024
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational studyIona Campo Le Brun, Séphane Dalle, Laurent Mortier, et al.
Journal of Hypertension|September 1, 2007
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS studyJoël Constans, Christine Germain, Philippe Gosse, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM networkRobin Zagala, Stephane Dalle, Marie Beylot-Barry, et al.
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2013
(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trialFlorent Cachin, Elisabeth Miot-Noirault, Brigitte Gillet, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
Pageof 4